News and Trends 31 Mar 2021 Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells The Dutch biotech startup Lava Therapeutics launched onto the Nasdaq stock market last week with an €85.6M ($100.5M) IPO. This is a sign of mounting investor interest in cancer treatments based on immune cells known as gamma delta T cells. The proceeds of the IPO will be used to drive the development of the company’s […] March 31, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
In Depth 31 Mar 2021 Equity Crowdfunding for Biotech Startups: Does It Work? In the last decade, crowdfunding has become a popular way to finance all sorts of projects and products. Biotech is no exception, but many question whether the high risk and long term nature of investing in the biotech industry makes it a good fit for equity crowdfunding. When you hear the term crowdfunding, you might […] March 31, 2021 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2021 Global Funding for Meat Alternative Companies Tripled in 2020 Companies developing sustainable meat and dairy alternatives smashed records with a €2.6B ($3.1B) haul last year. Why has it been such a bumper harvest? Traditional agriculture is a major polluter, especially in the case of meat production. The highest estimations place its share of global greenhouse gas emissions at up to 20%. In an effort […] March 24, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 21 May 2020 What 2019 Can Teach About European Biotech Investments Going Forward Following 2018’s bumper harvest for equity funding in European biotech, 2019 proved even more lucrative, particularly for private biotech companies. What are the biggest investment lessons learned from 2019, and how could Covid-19 change the dynamic in 2020? With the coronavirus pandemic thrusting global industry sectors into chaos, investors and entrepreneurs need to understand the […] May 21, 2020 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 6 Apr 2020 How Investors Can Prepare for the Digitization of Biotech For a few decades, the worlds of biotech and digital technology have been on separate paths. Franck Lescure, Partner at the French VC firm Elaia Partners, explains how the two fields are now colliding and how investors need to catch up. At first glance, digital technology and biotech are widely different fields, each with their […] April 6, 2020 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2020 Italian Investment Firm AurorA Science Launches to Support Early Stage Biotechs Italian technology transfer company AurorA-TT has joined forces with drug discovery companies Rottapharm Biotech and Italfarmaco to launch the biotech investment enterprise AurorA Science to support early stage biotechs. The partnership plans to invest €1–5M in each of one or two European start-ups this year. It is particularly focusing on promising biotechs in any area […] February 14, 2020 - 2 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
In Depth 11 Feb 2020 Why European Biotechs Should Look to China for Investment Traditionally European biotechs have looked to the US for additional investment, but changes in the law and significant economic success in the country in recent years means that new opportunities are opening up in China that are ripe for exploitation. China has a massive population and a correspondingly large patient group. Homegrown science is pretty […] February 11, 2020 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Expert Advice 15 Jan 2020 How to Spot a Biotech Winner: Investment Lessons from Sofinnova Making one biotech a success is hard enough, but correctly predicting multiple winners is the bread and butter of Antoine Papiernik, Managing Partner of Sofinnova Partners, one of the biggest and most prosperous life science venture capital investors in Europe. Papiernik began his career in corporate finance. In 1995, he was working in investment in […] January 15, 2020 - 10 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 8 Oct 2019 Biotech Hubs: A Tale of Two Cities Life science investors differ widely across biotech hubs in Europe. At Labiotech’s recent Refresh event, two investors from Cambridge and Paris compared the progress of these hubs and discussed the challenges that need to be overcome in biotech investment. Funding is the lifeblood of early biotech startups, and investors are a crucial supplier. For this […] October 8, 2019 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Opinion 30 Sep 2019 Can European Biotech Companies Afford Not to Work with China? In the current trade standoff between the US and China, Europe has a golden opportunity to gain a competitive advantage. At every healthcare conference I’ve been to recently in the US or Europe, the same question is being debated on panels: Should you or should you not have a China strategy as a biotech CEO? […] September 30, 2019 - 4 minutesmins - By Antoine Papiernik Share WhatsApp Twitter Linkedin Email
Opinion 16 Jul 2019 The Business of Biotech: What to Do When the S*#t Hits the Fan From CEO-itis to FDA-itis, the path of a biotech company is never dull. Whether the oft-repeated saying, “may you live in interesting times,” is a blessing or a curse depends entirely on your perspective. As a life science venture capital investor with close to 25 years of experience, I have encountered many unexpected and interesting […] July 16, 2019 - 5 minutesmins - By Antoine Papiernik Share WhatsApp Twitter Linkedin Email